Company news
TileBio closes £2.261M seed round
Seed round closed at £2.261M, led by Twin Path Ventures, to validate our technology in preclinical toxicology and exploratory biomarker discovery.
Chris Walsh
Read the note →Insights
Research notes and company news.
Methods, lessons from pilot studies, and company milestones.
Company news
TileBio secures £1.6M investment to launch AI ‘language of cancer’ diagnostic technology
Seed funding led by Twin Path Ventures to accelerate development of the tissue-language foundation model.
Chris Walsh
Read the note →
Company news
Terrain Life Science and Tile Advance a Strategic Collaboration in AI-Powered Precision Medicine
A collaboration combining Terrain’s spatial proteomics with TileBio’s pathology foundation models for biomarker discovery.
Chris Walsh
Read the note →
Company news
TileBio raising £2 Million seed round to transform pathology
Why we’re building the language of pathology.
Chris Walsh
Read the note →Discuss a study
Tell us about your cohort and the question you want to answer.